Michael R. Hayden
Genetics has allowed medicine to move beyond treating symptoms and start treating the underlying causes of disease.
"No diseases are hopeless anymore," says Dr. Hayden. "The way I see them is that their secrets have just not yet been identified."
Dr. Hayden’s work focuses on understanding the genetic roots of illness and using that understanding to develop better approaches to treatment for patients. He researches diabetes, coronary artery disease, and is part of a large collaboration to determine the genetic basis for adverse drug reactions in children. Much of his career has also been dedicated to understanding the development of Huntington disease and finding a way to cure it.
"When we started working on Huntington disease, the future was dark and patients and families felt hopeless," says Dr. Hayden. "Today, that has all changed."
Researchers in the Hayden laboratory have found a critical pathway in the development of juvenile forms of Huntington’s disease. Blocking the action of caspase-6 prevents the progression of the disease in mice. This finding could lay the groundwork for an effective approach to therapy for Huntington disease.
MAJOR ACHIEVEMENTS & PUBLICATIONS
Induction to the Canadian Medical Hall of Fame- 2017
One of 100 most inspirational and influential persons in Pharma, Pharmavoice - 2015
Honorary Doctor of Science, University of Gottingen - 2014
Luminary Award, Personalized Medicine World Conference - 2014
Named one of 50 Canadians born in the 20th century who have changed the world (along with Pierre Elliott Trudeau, Leonard Cohen, Oscar Peterson and John Kenneth Galbraith) - 2013
The Diamond Jubilee Medal, on behalf of HRH Queen Elizabeth II - 2012
Champions of Genetics, The Canadian Gene Cure Foundation (CGCF) - 2011
Aubrey J. Tingle Prize, Michael Smith Foundation for Health Research – 2011
Killam Prize, Canada Council of the Arts – 2011
Margolese National Prize, University of British Columbia – 2011
Canada Gairdner Wightman, Gairdner Foundation – 2011
Genome BC Award for Scientific Excellence, LifeSciences British Columbia – 2011
Order of Canada – 2010
Order of British Columbia – 2009
Canada's Health Researcher of the Year: Canadian Institutes of Health Research Michael Smith Prize in Biomedical and Clinical Research – 2008
Prix Galien (Canada) – 2007
Aminkeng F, Bhavasar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJD The Canadian Pharmacogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 47(9):1079-84. PMID:26237429
Southwell AL, Smith SEP, Davis T, Caron NS, Villanueva EB, Xie Y, Collins JA, Ye E, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015; 15(5):12166. PMID:26174131